Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Dupixent
|
| gptkbp:activities |
inhibits IL-4 and IL-13 signaling
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:2017
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:clinical_trial |
Phase 3
long-term management |
| gptkbp:contraindication |
hypersensitivity to dupilumab
|
| gptkbp:developed_by |
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals |
| gptkbp:education |
importance of adherence to therapy
advise on potential side effects instruct on injection technique |
| gptkbp:financial_performance |
stable until expiration date
|
| gptkbp:formulation |
solution for injection
|
| gptkbp:frequency |
every 2 weeks
initial loading dose |
| https://www.w3.org/2000/01/rdf-schema#label |
Dupilumab
|
| gptkbp:indication |
chronic rhinosinusitis with nasal polyps
moderate to severe atopic dermatitis eosinophilic esophagitis moderate to severe asthma |
| gptkbp:ingredients |
C30 H32 N6 O7 S
|
| gptkbp:interacts_with |
no significant drug interactions
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
monitor for allergic reactions
monitor for eosinophilia monitor for ocular symptoms |
| gptkbp:is_used_for |
gptkb:asthma
atopic dermatitis chronic rhinosinusitis with nasal polyps |
| gptkbp:manager |
subcutaneous
|
| gptkbp:marketed_as |
gptkb:Dupixent
|
| gptkbp:packaging |
auto-injector
pre-filled syringe |
| gptkbp:pharmacokinetics |
half-life of approximately 26 days
|
| gptkbp:population |
adults
children over 6 years old |
| gptkbp:price |
high cost
|
| gptkbp:provides_information_on |
included in treatment guidelines
|
| gptkbp:research_focus |
autoimmune diseases
allergic diseases chronic inflammatory diseases |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
headache
urticaria injection site reactions conjunctivitis pharyngitis |
| gptkbp:storage |
refrigerated at 2-8° C
|
| gptkbp:targets |
gptkb:IL-13_receptor
gptkb:IL-4_receptor |
| gptkbp:weight |
600.7 g/mol
|